Organon & Co. (NYSE:OGN) Shares Sold by Sage Rhino Capital LLC

Sage Rhino Capital LLC trimmed its holdings in Organon & Co. (NYSE:OGN) by 5.4% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 15,070 shares of the company’s stock after selling 852 shares during the period. Sage Rhino Capital LLC’s holdings in Organon & Co. were worth $225,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds have also modified their holdings of OGN. Pacer Advisors Inc. grew its holdings in shares of Organon & Co. by 94,482.1% in the fourth quarter. Pacer Advisors Inc. now owns 11,152,179 shares of the company’s stock valued at $166,391,000 after purchasing an additional 11,140,388 shares during the period. Weiss Asset Management LP purchased a new stake in shares of Organon & Co. in the third quarter valued at about $32,966,000. Jacobs Levy Equity Management Inc. grew its holdings in shares of Organon & Co. by 303.8% in the third quarter. Jacobs Levy Equity Management Inc. now owns 1,242,135 shares of the company’s stock valued at $23,762,000 after purchasing an additional 934,505 shares during the period. Charles Schwab Investment Management Inc. grew its holdings in shares of Organon & Co. by 35.7% in the third quarter. Charles Schwab Investment Management Inc. now owns 3,323,051 shares of the company’s stock valued at $63,570,000 after purchasing an additional 875,128 shares during the period. Finally, Philip James Wealth Mangement LLC purchased a new stake in shares of Organon & Co. in the third quarter valued at about $15,386,000. 77.43% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

OGN has been the subject of a number of analyst reports. TD Cowen raised shares of Organon & Co. to a “hold” rating in a report on Wednesday, January 15th. Morgan Stanley dropped their price objective on shares of Organon & Co. from $17.00 to $16.00 and set an “equal weight” rating for the company in a report on Friday, February 14th. Finally, Barclays lowered their target price on shares of Organon & Co. from $26.00 to $24.00 and set an “overweight” rating for the company in a research note on Friday, February 14th. One research analyst has rated the stock with a sell rating, three have issued a hold rating, two have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $20.80.

Organon & Co. Trading Down 3.8 %

Shares of OGN stock opened at $14.35 on Tuesday. The company has a debt-to-equity ratio of 17.73, a current ratio of 1.70 and a quick ratio of 1.21. The firm has a market cap of $3.70 billion, a PE ratio of 4.31, a price-to-earnings-growth ratio of 0.90 and a beta of 0.76. The company has a 50-day moving average of $15.43 and a two-hundred day moving average of $17.05. Organon & Co. has a 1-year low of $13.87 and a 1-year high of $23.10.

Organon & Co. (NYSE:OGN) last announced its earnings results on Thursday, February 13th. The company reported $0.83 earnings per share for the quarter, missing the consensus estimate of $0.92 by ($0.09). The company had revenue of $1.59 billion for the quarter, compared to analysts’ expectations of $1.57 billion. Organon & Co. had a return on equity of 431.62% and a net margin of 13.49%. On average, analysts predict that Organon & Co. will post 3.68 EPS for the current year.

Organon & Co. Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, March 13th. Stockholders of record on Monday, February 24th will be given a dividend of $0.28 per share. The ex-dividend date of this dividend is Monday, February 24th. This represents a $1.12 annualized dividend and a dividend yield of 7.80%. Organon & Co.’s dividend payout ratio is presently 33.63%.

Organon & Co. Profile

Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.